{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T15:33:43Z","timestamp":1791387223015,"version":"4.3.3"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,29]],"date-time":"2022-11-29T00:00:00Z","timestamp":1669680000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,29]],"date-time":"2022-11-29T00:00:00Z","timestamp":1669680000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Aggregated amyloid-\u03b2 (A\u03b2) is considered a pathogenic initiator of Alzheimer\u2019s disease (AD), in strong association with tau hyperphosphorylation, neuroinflammation, synaptic dysfunction, and cognitive decline. As the removal of amyloid burden from AD patient brains by antibodies has shown therapeutic potential, the development of small molecule drugs inducing chemical dissociation and clearance of A\u03b2 is compelling as a therapeutic strategy. In this study, we synthesized and screened aryloxypropanolamine derivatives and identified 1-(3-(2,4-di-tert-pentylphenoxy)-2-hydroxypropyl)pyrrolidin-1-ium chloride, YIAD002, as a strong dissociator of A\u03b2 aggregates.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The dissociative activity of aryloxypropanolamine derivatives against A\u03b2 aggregates were evaluated through in vitro assays. Immunohistochemical staining, immunoblot assays, and the Morris water maze were used to assess the anti-Alzheimer potential in YIAD002-treated 5XFAD and transgenic APP\/PS1 mice. Target-ligand interaction mechanism was characterized via a combination of peptide mapping, fluorescence dissociation assays, and constrained docking simulations.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Among 11 aryloxypropanolamine derivatives, YIAD002 exerted strongest dissociative activity against \u03b2-sheet-rich A\u03b2 aggregates. Upon oral administration, YIAD002 substantially reduced amyloid burden and accordingly, improved cognitive performance in the Morris water maze and attenuated major pathological hallmarks of AD including tauopathy, neuroinflammation, and synaptic protein loss. Mechanism studies suggest that YIAD002 interferes with intermolecular \u03b2-sheet fibrillation by directly interacting with KLVFFA and IGLMVG domains of A\u03b2. In addition, YIAD002 was found to possess dissociative activity against aggregates of pyroglutamate-modified A\u03b2 and tau.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Collectively, our results evince the potential of chemical-driven dissociation of A\u03b2 aggregates by aryloxypropanolamines as a therapeutic modality of the amyloid clearance approach.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13195-022-01112-6","type":"journal-article","created":{"date-parts":[[2022,11,29]],"date-time":"2022-11-29T07:30:23Z","timestamp":1669707023000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Aryloxypropanolamine targets amyloid aggregates and reverses Alzheimer-like phenotypes in Alzheimer mouse models"],"prefix":"10.1186","volume":"14","author":[{"given":"Hee Yang","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soljee","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeong Hwa","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keunwan","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youngeun","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Illhwan","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donghee","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jisu","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyeonghwan","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunmi","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jimin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koeun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung Hoon","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seong Muk","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hye Ju","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hye Yun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ikyon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young Soo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,29]]},"reference":[{"issue":"7","key":"1112_CR1","doi-asserted-by":"publisher","first-page":"a006338-a","DOI":"10.1101\/cshperspect.a006338","volume":"2","author":"L Mucke","year":"2012","unstructured":"Mucke L, Selkoe DJ. Neurotoxicity of amyloid \u03b2-protein: synaptic and network dysfunction. Cold Spring Harb Perspect Med. 2012;2(7):a006338-a.","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"9","key":"1112_CR2","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1038\/aps.2017.28","volume":"38","author":"G-f Chen","year":"2017","unstructured":"Chen G-f, Xu T-h, Yan Y, Zhou Y-r, Jiang Y, Melcher K, et al. Amyloid beta: structure, biology and structure-based therapeutic development. Acta Pharmacol Sin. 2017;38(9):1205\u201335.","journal-title":"Acta Pharmacol Sin"},{"issue":"18","key":"1112_CR3","doi-asserted-by":"publisher","first-page":"3507","DOI":"10.1007\/s00018-014-1634-z","volume":"71","author":"E Hubin","year":"2014","unstructured":"Hubin E, van Nuland NAJ, Broersen K, Pauwels K. Transient dynamics of A\u03b2 contribute to toxicity in Alzheimer\u2019s disease. Cell Mol Life Sci. 2014;71(18):3507\u201321.","journal-title":"Cell Mol Life Sci"},{"issue":"7618","key":"1112_CR4","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/nature19323","volume":"537","author":"J Sevigny","year":"2016","unstructured":"Sevigny J, Chiao P, Bussi\u00e8re T, Weinreb PH, Williams L, Maier M, et al. The antibody aducanumab reduces A\u03b2 plaques in Alzheimer\u2019s disease. Nature. 2016;537(7618):50\u20136.","journal-title":"Nature."},{"issue":"2","key":"1112_CR5","doi-asserted-by":"publisher","first-page":"417","DOI":"10.3233\/JAD-160122","volume":"52","author":"F Piazza","year":"2016","unstructured":"Piazza F, Winblad B. Amyloid-related imaging abnormalities (ARIA) in immunotherapy trials for Alzheimer\u2019s disease: need for prognostic biomarkers? J Alzheimers Dis. 2016;52(2):417\u201320.","journal-title":"J Alzheimers Dis"},{"key":"1112_CR6","doi-asserted-by":"crossref","unstructured":"Low KJY, Venkatraman A, Mehta JS, Pervushin K. Molecular mechanisms of amyloid disaggregation. J Adv Res. 2021;36:113\u201332.","DOI":"10.1016\/j.jare.2021.05.007"},{"issue":"1","key":"1112_CR7","doi-asserted-by":"publisher","first-page":"8997","DOI":"10.1038\/ncomms9997","volume":"6","author":"HY Kim","year":"2015","unstructured":"Kim HY, Kim HV, Jo S, Lee CJ, Choi SY, Kim DJ, et al. EPPS rescues hippocampus-dependent cognitive deficits in APP\/PS1 mice by disaggregation of amyloid-\u03b2 oligomers and plaques. Nat Commun. 2015;6(1):8997.","journal-title":"Nat Commun"},{"issue":"51","key":"1112_CR8","doi-asserted-by":"publisher","first-page":"22994","DOI":"10.1002\/anie.202009294","volume":"59","author":"Y Kwon","year":"2020","unstructured":"Kwon Y, Shin J, Nam K, An JS, Yang S-H, Hong S-H, et al. Rhizolutin, a novel 7\/10\/6-tricyclic dilactone, dissociates misfolded protein aggregates and reduces apoptosis\/inflammation associated with Alzheimer\u2019s disease. Angew Chem Int Ed. 2020;59(51):22994\u20138.","journal-title":"Angew Chem Int Ed"},{"issue":"28","key":"1112_CR9","doi-asserted-by":"publisher","first-page":"11491","DOI":"10.1002\/anie.202002574","volume":"59","author":"JC Lee","year":"2020","unstructured":"Lee JC, Kim HY, Lee S, Shin J, Kim HV, Kim K, et al. Discovery of chemicals to either clear or indicate amyloid aggregates by targeting memory-impairing anti-parallel A\u03b2 dimers. Angew Chem Int Ed. 2020;59(28):11491\u2013500.","journal-title":"Angew Chem Int Ed"},{"issue":"4","key":"1112_CR10","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.tips.2011.02.010","volume":"32","author":"JG Baker","year":"2011","unstructured":"Baker JG, Hill SJ, Summers RJ. Evolution of \u03b2-blockers: from anti-anginal drugs to ligand-directed signalling. Trends Pharmacol Sci. 2011;32(4):227\u201334.","journal-title":"Trends Pharmacol Sci"},{"issue":"3","key":"1112_CR11","doi-asserted-by":"publisher","first-page":"133","DOI":"10.3109\/13506129.2012.700287","volume":"19","author":"JW Choi","year":"2012","unstructured":"Choi JW, Kim HY, Jeon M, Kim DJ, Kim Y. Efficient access to highly pure \u03b2-amyloid peptide by optimized solid-phase synthesis. Amyloid. 2012;19(3):133\u20137.","journal-title":"Amyloid."},{"issue":"3","key":"1112_CR12","doi-asserted-by":"publisher","first-page":"185","DOI":"10.3109\/13506129.2014.929103","volume":"21","author":"MM Haque","year":"2014","unstructured":"Haque MM, Kim D, Yu YH, Lim S, Kim DJ, Chang YT, et al. Inhibition of tau aggregation by a rosamine derivative that blocks tau intermolecular disulfide cross-linking. Amyloid. 2014;21(3):185\u201390.","journal-title":"Amyloid."},{"key":"1112_CR13","doi-asserted-by":"publisher","first-page":"7829842","DOI":"10.1155\/2020\/7829842","volume":"2020","author":"SJ Shin","year":"2020","unstructured":"Shin SJ, Park YH, Jeon SG, Kim S, Nam Y, Oh S-M, et al. Red ginseng inhibits tau aggregation and promotes tau dissociation in vitro. Oxid Med Cell Longev. 2020;2020:7829842.","journal-title":"Oxid Med Cell Longev"},{"issue":"1","key":"1112_CR14","doi-asserted-by":"publisher","DOI":"10.1098\/rsos.160696","volume":"4","author":"C Xue","year":"2017","unstructured":"Xue C, Lin TY, Chang D, Guo Z. Thioflavin T as an amyloid dye: fibril quantification, optimal concentration and effect on aggregation. R Soc Open Sci. 2017;4(1):160696.","journal-title":"R Soc Open Sci"},{"issue":"15","key":"1112_CR15","doi-asserted-by":"publisher","first-page":"eaaz6014","DOI":"10.1126\/sciadv.aaz6014","volume":"6","author":"PN Nirmalraj","year":"2020","unstructured":"Nirmalraj PN, List J, Battacharya S, Howe G, Xu L, Thompson D, et al. Complete aggregation pathway of amyloid \u03b2 (1-40) and (1-42) resolved on an atomically clean interface. Sci Adv. 2020;6(15):eaaz6014.","journal-title":"Sci Adv"},{"issue":"6","key":"1112_CR16","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1111\/j.1742-4658.2010.07568.x","volume":"277","author":"M Sakono","year":"2010","unstructured":"Sakono M, Zako T. Amyloid oligomers: formation and toxicity of A\u03b2 oligomers. FEBS J. 2010;277(6):1348\u201358.","journal-title":"FEBS J"},{"issue":"6","key":"1112_CR17","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1021\/ar000214l","volume":"37","author":"G Bitan","year":"2004","unstructured":"Bitan G, Teplow DB. Rapid photochemical cross-linking a new tool for studies of metastable, amyloidogenic protein assemblies. Acc Chem Res. 2004;37(6):357\u201364.","journal-title":"Acc Chem Res"},{"issue":"40","key":"1112_CR18","doi-asserted-by":"publisher","first-page":"10129","DOI":"10.1523\/JNEUROSCI.1202-06.2006","volume":"26","author":"H Oakley","year":"2006","unstructured":"Oakley H, Cole SL, Logan S, Maus E, Shao P, Craft J, et al. Intraneuronal \u03b2-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer\u2019s disease mutations: potential factors in amyloid plaque formation. J Neurosci. 2006;26(40):10129\u201340.","journal-title":"J Neurosci"},{"issue":"3","key":"1112_CR19","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.neuron.2004.07.003","volume":"43","author":"S Oddo","year":"2004","unstructured":"Oddo S, Billings L, Kesslak JP, Cribbs DH, LaFerla FM. A\u03b2 Immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron. 2004;43(3):321\u201332.","journal-title":"Neuron."},{"issue":"1","key":"1112_CR20","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1038\/s41598-021-81304-6","volume":"11","author":"J Shin","year":"2021","unstructured":"Shin J, Park S, Lee H, Kim Y. Thioflavin-positive tau aggregates complicating quantification of amyloid plaques in the brain of 5XFAD transgenic mouse model. Sci Rep. 2021;11(1):1617.","journal-title":"Sci Rep"},{"issue":"4","key":"1112_CR21","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/S1474-4422(15)70016-5","volume":"14","author":"MT Heneka","year":"2015","unstructured":"Heneka MT, Carson MJ, Khoury JE, Landreth GE, Brosseron F, Feinstein DL, et al. Neuroinflammation in Alzheimer\u2019s disease. Lancet Neurol. 2015;14(4):388\u2013405.","journal-title":"Lancet Neurol"},{"issue":"11","key":"1112_CR22","doi-asserted-by":"publisher","first-page":"3592","DOI":"10.1016\/j.celrep.2019.11.044","volume":"29","author":"EK Pickett","year":"2019","unstructured":"Pickett EK, Herrmann AG, McQueen J, Abt K, Dando O, Tulloch J, et al. Amyloid beta and tau cooperate to cause reversible behavioral and transcriptional deficits in a model of Alzheimer\u2019s disease. Cell Rep. 2019;29(11):3592\u2013604.e5.","journal-title":"Cell Rep"},{"issue":"2","key":"1112_CR23","doi-asserted-by":"publisher","first-page":"541","DOI":"10.3233\/JAD-2010-100948","volume":"22","author":"J Liu","year":"2010","unstructured":"Liu J, Chang L, Roselli F, Almeida OF, Gao X, Wang X, et al. Amyloid-\u03b2 induces caspase-dependent loss of PSD-95 and synaptophysin through NMDA receptors. J Alzheimers Dis. 2010;22(2):541\u201356.","journal-title":"J Alzheimers Dis"},{"issue":"7","key":"1112_CR24","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1021\/jm970530e","volume":"41","author":"M Kansy","year":"1998","unstructured":"Kansy M, Senner F, Gubernator K. Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes. J Med Chem. 1998;41(7):1007\u201310.","journal-title":"J Med Chem"},{"issue":"3","key":"1112_CR25","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/S0223-5234(03)00012-6","volume":"38","author":"L Di","year":"2003","unstructured":"Di L, Kerns EH, Fan K, McConnell OJ, Carter GT. High throughput artificial membrane permeability assay for blood-brain barrier. Eur J Med Chem. 2003;38(3):223\u201332.","journal-title":"Eur J Med Chem"},{"key":"1112_CR26","doi-asserted-by":"publisher","first-page":"137-II","DOI":"10.1016\/B978-012369520-8.50012-7","volume-title":"Drug-like properties: concepts, structure design and methods","author":"EH Kerns","year":"2008","unstructured":"Kerns EH, Di L. Chapter 11 - Metabolic stability. In: Kerns EH, Di L, editors. Drug-like properties: concepts, structure design and methods. San Diego: Academic Press; 2008. p. 137-II."},{"issue":"1","key":"1112_CR27","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.ijpharm.2005.03.022","volume":"297","author":"L Di","year":"2005","unstructured":"Di L, Kerns EH, Hong Y, Chen H. Development and application of high throughput plasma stability assay for drug discovery. Int J Pharm. 2005;297(1):110\u20139.","journal-title":"Int J Pharm"},{"issue":"2","key":"1112_CR28","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.bbadis.2004.09.010","volume":"1739","author":"M von Bergen","year":"2005","unstructured":"von Bergen M, Barghorn S, Biernat J, Mandelkow E-M, Mandelkow E. Tau aggregation is driven by a transition from random coil to beta sheet structure. Biochim Biophys Acta, Mol Basis Dis. 2005;1739(2):158\u201366.","journal-title":"Biochim Biophys Acta, Mol Basis Dis"},{"issue":"1","key":"1112_CR29","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/s41467-017-00480-0","volume":"8","author":"S Ambadipudi","year":"2017","unstructured":"Ambadipudi S, Biernat J, Riedel D, Mandelkow E, Zweckstetter M. Liquid\u2013liquid phase separation of the microtubule-binding repeats of the Alzheimer-related protein Tau. Nat Commun. 2017;8(1):275.","journal-title":"Nat Commun"},{"issue":"1","key":"1112_CR30","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s13024-019-0329-1","volume":"14","author":"RM Meade","year":"2019","unstructured":"Meade RM, Fairlie DP, Mason JM. Alpha-synuclein structure and Parkinson\u2019s disease \u2013 lessons and emerging principles. Mol Neurodegener. 2019;14(1):29.","journal-title":"Mol Neurodegener"},{"issue":"2","key":"1112_CR31","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/0022-2836(92)90835-8","volume":"228","author":"C Hilbich","year":"1992","unstructured":"Hilbich C, Kisters-Woike B, Reed J, Masters CL, Beyreuther K. Substitutions of hydrophobic amino acids reduce the amyloidogenicity of Alzheimer\u2019s disease beta A4 peptides. J Mol Biol. 1992;228(2):460\u201373.","journal-title":"J Mol Biol"},{"issue":"2","key":"1112_CR32","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1021\/bi051952q","volume":"45","author":"AT Petkova","year":"2006","unstructured":"Petkova AT, Yau W-M, Tycko R. Experimental constraints on quaternary structure in Alzheimer\u2019s \u03b2-amyloid fibrils. Biochemistry. 2006;45(2):498\u2013512.","journal-title":"Biochemistry."},{"issue":"1","key":"1112_CR33","doi-asserted-by":"publisher","first-page":"61","DOI":"10.15252\/emmm.201606566","volume":"9","author":"S-H Yang","year":"2017","unstructured":"Yang S-H, Lee DK, Shin J, Lee S, Baek S, Kim J, et al. Nec-1 alleviates cognitive impairment with reduction of A\u03b2 and tau abnormalities in APP\/PS1 mice. EMBO Mol Med. 2017;9(1):61\u201377.","journal-title":"EMBO Mol Med"},{"key":"1112_CR34","first-page":"496","volume-title":"FDA approval for Biogen\u2019s aducanumab sparks Alzheimer disease firestorm","author":"A Mullard","year":"2021","unstructured":"Mullard A. FDA approval for Biogen\u2019s aducanumab sparks Alzheimer disease firestorm, vol. 20; 2021. p. 496."}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-022-01112-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13195-022-01112-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-022-01112-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,29]],"date-time":"2022-11-29T17:53:52Z","timestamp":1669744432000},"score":1,"resource":{"primary":{"URL":"https:\/\/alzres.biomedcentral.com\/articles\/10.1186\/s13195-022-01112-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,29]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["1112"],"URL":"https:\/\/doi.org\/10.1186\/s13195-022-01112-6","relation":{},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,29]]},"assertion":[{"value":"17 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Protocols involving transgenic mice were approved by IACUC of the Yonsei Laboratory Animal Research Center and NDIC Inc. (Kyunggido, Korea; approval No. P191114).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"SHH, SMK, HJK, and YSK are employees of Amyloid Solution, received equity or equity options, and contributed to the current investigation.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"177"}}